Treatment with liraglutide (dose range: 0.3 to 0.9 mg/day) for 20.0 ± 6.4 days significantly reduced waist
circumference, waist/hip ratio, eVFA. It also significantly improved the scores of eating behavior, food preference
and the urge for fat intake and tended to reduce scores for sense of hunger. Liraglutide increased serum C-peptide
immunoreactivity and disposition index.